Status:
RECRUITING
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Lead Sponsor:
AbbVie
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
March 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
698 Patients enrolled
Trial Details
Trial ID
NCT04928846
Start Date
March 25 2022
End Date
March 1 2028
Last Update
March 13 2026
Active Locations (315)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham - Main /ID# 247074
Birmingham, Alabama, United States, 35233
2
Ironwood Cancer & Res Ctr /ID# 262446
Chandler, Arizona, United States, 85224-5665
3
Mayo Clinic Arizona /ID# 255858
Phoenix, Arizona, United States, 85054-4504
4
Onvida Health Yuma Medical Center /ID# 253625
Yuma, Arizona, United States, 85364